BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 20418207)

  • 1. [Advanced renal carcinomas with special situations. How to treat them?].
    Pouessel D; Patard JJ; Culine S
    Bull Cancer; 2010; 97():83-90. PubMed ID: 20418207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renal cell carcinoma management and therapies in 2010].
    Albouy B; Gross Goupil M; Escudier B; Massard C
    Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of angiogenesis inhibitors on renal cell carcinoma].
    Bodrogi I
    Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiogenesis targeting in renal carcinomas].
    Pouessel D; Culine S
    Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Tuma RS
    J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
    Vanhuyse M; Penel N; Caty A; Fumagalli I; Alt M; Zini L; Adenis A
    Bull Cancer; 2012 Dec; 99(12):100-6. PubMed ID: 23220100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
    Pouessel D; Culine S
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic therapy for metastatic renal cell carcinoma.
    Kroog GS; Motzer RJ
    Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
    de Mulder PH; Haanen JB; Sleijfer S; Kruit WH; Gietema JA; Richel DJ; Groenewegen G; Voest EE; van den Eertwegh AJ; Osanto S; Jansen RL; Mulders PF
    Ned Tijdschr Geneeskd; 2008 Feb; 152(7):371-5. PubMed ID: 18380383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM
    J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Targeted therapies: sequential and combined treatments].
    Gross-Goupil M; Escudier B
    Bull Cancer; 2010; 97():65-71. PubMed ID: 20418205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renal cell carcinoma and antiangiogenic therapies].
    Pouessel D; Culine S; Verhoest G; Patard JJ
    Presse Med; 2008 Apr; 37(4 Pt 2):628-33. PubMed ID: 18035517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
    Heng DY; Mackenzie MJ; Vaishampayan UN; Bjarnason GA; Knox JJ; Tan MH; Wood L; Wang Y; Kollmannsberger C; North S; Donskov F; Rini BI; Choueiri TK
    Ann Oncol; 2012 Jun; 23(6):1549-55. PubMed ID: 22056973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
    Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular biology of renal cell carcinoma.
    Mellado B; Gascón P
    Clin Transl Oncol; 2006 Oct; 8(10):706-10. PubMed ID: 17074668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.